1151MO Pathological Response is an Independent Factor of Overall Survival and Disease-Free Survival after Neoadjuvant Durvalumab in Resectable Non-Small Cell Lung Cancer (NSCLC) in the IFCT-1601 IONESCO Phase II Trial
Annals of Oncology（2021）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined